



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.		APPLICATION NO.	
				8907-076-999		09/216,028	
				APPLICANT			
				Feder et al.		GROUP	
FILING DATE				December 18, 1998		1654	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
Aa	AA	Dadone et al., 1982, "Analysis of laboratory expression of the disease by genotype in 18 pedigrees", <i>AM. J. Clin. Pathol.</i> 78:196-207					
1	AB	Edwards et al., 1988, "Prevalence of Hemochromatosis Among 11,065 Presumably Healthy Blood Donors", <i>N. Engl. J. Med.</i> 18:1355-1362					
	AC	Feder et al., 1998, "The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 95:1472-1477					
	AD	Feder et al., 1996, "A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis", <i>Nature Genetics</i> 13:399-408					
	AE	Feder et al., 1997, "The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression", <i>J. Biol. Chem.</i> 272: 14025-14028					
	AF	Gross et al., 1998, "Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation", <i>J. Biol. Chem.</i> 273:22068-22074					
	AG	Kosbor et al., 1983, "The production of monoclonal antibodies from human lymphocytes", <i>Immunology Today</i> 4:72					
	AH	Lebron et al., 1998, "Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor", <i>Cell</i> 93:111-123					
	AI	McLaren et al., 1995, "Prevalence of heterozygotes for hemochromatosis in the white population of the United States", <i>Blood</i> 86:2021-2027					
	AL	Sampietro et al., 1998, "High prevalence of the His63 Asp HFE mutation in Italian patients with porphyria cutanea tarda", <i>Hepatology</i> 27:181-184					
	Am	Stagsted et al., 1993, "Amino acid residues essential for biological activity of a peptide derived from a major histocompatibility complex class I antigen", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:7586-7590					
	AI	Stagsted et al., 1990, "Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen", <i>Cell</i> 62:297-307					
	AM	Van Landeghem et al., 1998, "Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma", <i>Lancet</i> 352:1285-1286					
Aa	AN	Yaouanq et al., 1997, "Hemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia", <i>Lancet</i> 349:1475-1476					
EXAMINER				DATE CONSIDERED			
							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET

8907-0076-999

APPLICATION NO

09/216,009

APPLICANT

Feder et al.

FILING DATE

December 18, 1998

GROUP

1653

10/23 U.S. PAT. 09/901956

07/09/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AO	AO	5,712,098	01/27/98	Tsuchihashi et al.	435	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AO	AP	WO 97/38137	10/16/97	PCT (Mercator Genetics Inc.)				
AO	AO	WO 98/56814	12/17/98	PCT (Progenitor, Inc.)				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

--	--	--

EXAMINER

[Signature]

DATE CONSIDERED

11/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.